Literature DB >> 16170169

Explaining differences in attitude toward adjuvant chemotherapy between experienced and inexperienced breast cancer patients.

S J T Jansen1, W Otten, M C M Baas-Thijssen, C J H van de Velde, J W R Nortier, A M Stiggelbout.   

Abstract

PURPOSE: Previous studies have shown that patients who have experienced adjuvant chemotherapy (experienced patients) have a more favorable attitude towards chemotherapy than those who have not (inexperienced patients). However, not much is known about the reasons underlying this difference. According to the Theory of Planned Behavior, the attitude towards a particular behavior (eg, accepting chemotherapy) is based on beliefs about the likelihood of outcomes of the behavior and the evaluations of these outcomes. We used this theory to explore in what way the beliefs of experienced patients differed from those of inexperienced patients. PATIENTS AND METHODS: A cross-sectional survey was undertaken among 719 patients who had been treated for early-stage breast cancer between 1998 and 2003. Patients were asked, first, to indicate the likelihood of six positive and six negative outcomes of undergoing chemotherapy and, second, to give their evaluation of these outcomes.
RESULTS: Four hundred forty-six women filled in the questionnaire (response rate, 62%). As hypothesized, experienced patients (ie, patients who had been treated with adjuvant chemotherapy as part of their primary treatment plan) had a more positive attitude towards chemotherapy. Experienced patients provided higher likelihood estimates of treatment advantages, such as life prolongation. In addition, they evaluated the positive outcomes of chemotherapy more favorably. With regard to the negative outcomes of chemotherapy, few differences were observed between treatment groups.
CONCLUSION: Experienced patients have more confidence in the positive outcomes of chemotherapy than inexperienced patients. This might be the result of a cognitive mechanism to justify the way in which patients were treated.

Entities:  

Mesh:

Year:  2005        PMID: 16170169     DOI: 10.1200/JCO.2005.07.171

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  8 in total

1.  Attitudes toward information about genetic risk for cognitive impairment after cancer chemotherapy: breast cancer survivors compared with healthy controls.

Authors:  Michael A Andrykowski; Jessica L Burris; Erin Walsh; Brent J Small; Paul B Jacobsen
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

Review 2.  Cognitive effects of cancer systemic therapy: implications for the care of older patients and survivors.

Authors:  Jeanne S Mandelblatt; Paul B Jacobsen; Tim Ahles
Journal:  J Clin Oncol       Date:  2014-07-28       Impact factor: 44.544

3.  Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians.

Authors:  Jeanne S Mandelblatt; Vanessa B Sheppard; Arti Hurria; Gretchen Kimmick; Claudine Isaacs; Kathryn L Taylor; Alice B Kornblith; Anne-Michelle Noone; Gheorghe Luta; Michelle Tallarico; William T Barry; Lisa Hunegs; Robin Zon; Michael Naughton; Eric Winer; Clifford Hudis; Stephen B Edge; Harvey Jay Cohen; Hyman Muss
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

4.  Lung cancer patients' decisions about clinical trials and the theory of planned behavior.

Authors:  Gwendolyn P Quinn; Christie L Pratt; Kathy Bryant-George; Vicki D Caraway; Bonnie Paternoster; Tere Roldan; Andrea Shaffer; Cynthia O Shimizu; Elizabeth J Vaughn; Charles Williams; Gerold Bepler
Journal:  J Cancer Educ       Date:  2011-12       Impact factor: 2.037

5.  A New Attitude Towards Treatment Measure Predicts Survival Over 17 Years.

Authors:  Gail Ironson; Emily Hylton; Rachel Verhagen
Journal:  J Gen Intern Med       Date:  2022-03-16       Impact factor: 6.473

6.  Response rates to a mailed survey of a representative sample of cancer patients randomly drawn from the Pennsylvania Cancer Registry: a randomized trial of incentive and length effects.

Authors:  Bridget J Kelly; Taressa K Fraze; Robert C Hornik
Journal:  BMC Med Res Methodol       Date:  2010-07-14       Impact factor: 4.615

Review 7.  Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know?

Authors:  Jeanne S Mandelblatt; Arti Hurria; Brenna C McDonald; Andrew J Saykin; Robert A Stern; John W VanMeter; Meghan McGuckin; Tiffani Traina; Neelima Denduluri; Scott Turner; Darlene Howard; Paul B Jacobsen; Tim Ahles
Journal:  Semin Oncol       Date:  2013-12       Impact factor: 4.929

8.  Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity?

Authors:  Jeanne S Mandelblatt; Robert A Stern; Gheorghe Luta; Meghan McGuckin; Jonathan D Clapp; Arti Hurria; Paul B Jacobsen; Leigh Anne Faul; Claudine Isaacs; Neelima Denduluri; Brandon Gavett; Tiffany A Traina; Patricia Johnson; Rebecca A Silliman; R Scott Turner; Darlene Howard; John W Van Meter; Andrew Saykin; Tim Ahles
Journal:  J Clin Oncol       Date:  2014-05-19       Impact factor: 44.544

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.